Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $418.00. The company’s shares closed ...

Mnwabisi Mbangata arrived at Vertex Pharmaceuticals almost two years ago with nearly a decade of experience — including five years at Eli Lilly in various roles — in bringing innovative therapies to ...

BUCHAREST, Jan 14 (Reuters) - A Romanian court lifted a house arrest order against internet personality Andrew Tate, replacing it with a lighter preventative measure pending the outcome of a ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled ...

Cut down on your TV expenses this year. Streaming offers variety, including live sports and news, all without the need for a contract. David reviews TVs and leads the Personal Tech team at CNET ...

AVDL opened at $7.90 on Thursday. The firm has a 50 day moving average price of $11.41 and a 200 day moving average price of $13.54. The company has a market cap of $761.26 million, a PE ratio of ...

Actress Cate Blanchett and her husband, Andrew Upton, have been together for almost 30 years, despite their romance starting as the definition of a whirlwind. It might be because they’re so well ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...